Evidence map›Paper›PMID 33213505›Full record

ArticleGenome biology2020

Deep sequencing reveals a DAP1 regulatory haplotype that potentiates autoimmunity in systemic lupus erythematosus.

Prithvi Raj, Ran Song, Honglin Zhu, Linley Riediger, Dong-Jae Jun, Chaoying Liang, Carlos Arana, Bo Zhang, Yajing Gao, Benjamin E Wakeland and 18 more

Open access · goldAbstract read
In one paragraph

Article in Genome biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Genetic haplotypes inJournal for immunotherapy of cancer · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 8 institutions in 3 countries.

Prithvi RajDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. prithvi.raj@utsouthwestern.edu.ORCID 0000-0003-4068-4358
Ran SongDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Honglin ZhuDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Linley RiedigerDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Dong-Jae JunDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Chaoying LiangDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Carlos AranaDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Bo ZhangDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Yajing GaoDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Benjamin E WakelandDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Igor DozmorovDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Jinchun ZhouDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Jennifer A KellyArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Bernard R LauwerysInstitut de Recherche Expérimentale et Clinique, Université catholique de Louvain, 1200, Bruxelles, Belgium.
Joel M GuthridgeArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Nancy J OlsenDivision of Rheumatology, Department of Medicine, Penn State Medical School, State College, PA, USA.
Swapan K NathArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Chandrashekhar PasareDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Nicolai van OersDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Gary GilkesonDivision of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Betty P TsaoDivision of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Patrick M GaffneyArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Peter K GregersenFeinstein Institute of Medical Research in Manhasset, New York, USA.
Judith A JamesArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Xiaoxia ZuoDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, 410008, China. susanzuo@csu.edu.cn.
David R KarpRheumatic Diseases Division, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Quan-Zhen LiDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. quan.li@utsouthwestern.edu.
Edward K WakelandDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. edward.wakeland@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USOklahoma Medical Research Foundation · USSouthwestern Medical Center · USCentral South University · CNMedical University of South Carolina · USFeinstein Institute for Medical Research · USPennsylvania State University · USUCLouvain · BE

Funding

Proteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DON C. ROCKEY · 2020 to 2026
$8.8M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5M
SLAM Genes-from Mouse to ManP50AR055503 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI DAVIS, LAURIE S · 2007 to 2011
$8.3M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Candidate Causal Variants in Systemic Lupus ErythematosusRC2AR058959 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M, WAKELAND, EDWARD K. · 2009 to 2010
$4.3M
Transancestral fine mapping and functional dissection of autophagy-related SLE risk lociR01AR071410 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LESSARD, CHRISTOPHER J, TSAO, BETTY P · 2018 to 2022
$3.5M
Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3M
SLE Susceptibility and Clinical Significance at 2q22-24 across Multiple EthnicitiR01AR060366 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI NATH, SWAPAN K. · 2010 to 2019
$3.3M
Mechanisms of Lupus Disease Transition and Hydroxychloroquine Immune ModulationR01AR072401 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2017 to 2020
$1.8M
NIAID NIH HHS U19 AI082714NIAID NIH HHS UM1 AI144292NIAMS NIH HHS P30 AR073750NIAMS NIH HHS P50 AR055503NIAMS NIH HHS R01 AR060366NIAMS NIH HHS R01 AR071410NIAMS NIH HHS R01 AR072401NIAMS NIH HHS RC2 AR058959NIDDK NIH HHS P30 DK123704NIH HHS AR060366
6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease characterized by the development of anti-nuclear antibodies. Susceptibility to SLE is multifactorial, with a combination of genetic and environmental risk factors contributing to disease development. Like other polygenic diseases, a significant proportion of estimated SLE heritability is not accounted for by common disease alleles analyzed by SNP array-based GWASs. Death-associated protein 1 (DAP1) was implicated as a candidate gene in a previous familial linkage study of SLE and rheumatoid arthritis, but the association has not been explored further.

resultsWe perform deep sequencing across the DAP1 genomic segment in 2032 SLE patients, and healthy controls, and discover a low-frequency functional haplotype strongly associated with SLE risk in multiple ethnicities. We find multiple cis-eQTLs embedded in a risk haplotype that progressively downregulates DAP1 transcription in immune cells. Decreased DAP1 transcription results in reduced DAP1 protein in peripheral blood mononuclear cells, monocytes, and lymphoblastoid cell lines, leading to enhanced autophagic flux in immune cells expressing the DAP1 risk haplotype. Patients with DAP1 risk allele exhibit significantly higher autoantibody titers and altered expression of the immune system, autophagy, and apoptosis pathway transcripts, indicating that the DAP1 risk allele mediates enhanced autophagy, leading to the survival of autoreactive lymphocytes and increased autoantibody.

conclusionsWe demonstrate how targeted sequencing captures low-frequency functional risk alleles that are missed by SNP array-based studies. SLE patients with the DAP1 genotype have distinct autoantibody and transcription profiles, supporting the dissection of SLE heterogeneity by genetic analysis.

Indexed as

HaplotypesHigh-Throughput Nucleotide SequencingAllelesApoptosis Regulatory ProteinsArthritis, RheumatoidAutoimmunityAutophagyDendritic CellsDown-RegulationGene ExpressionGene Expression ProfilingGene FrequencyGenetic Predisposition to DiseaseGenotypeHumansLeukocytes, MononuclearApoptosis Regulatory ProteinsDAP protein, humanAutophagyDAP1HaplotypeRNA-SeqSequencingSLESNPs

Identifiers

PMID33213505
PMCPMC7677828
OpenAlexW3099509584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.